Safety of Anlotinib Therapy
nausea, death, neutropenia, fatigue, diarrhea, hand foot syndrome, proteinuria, intratumoral hemorrhage, anemia, hemorrhage, hypertension, anorexia
NEUTROPENIA, HAND FOOT SYNDROME, ADVERSE EVENTS, ADVERSE EVENT, GASTROINTESTINAL BLEEDING, ANEMIA, HEMORRHAGE, HYPERTENSION, ANOREXIA
The most common adverse events related to anlotinib treatment were hypertension. Other common adverse events (>10%) include neutropenia, fatigue, anemia, anorexia, hand foot syndrome, nausea, proteinuria, diarrhea, and hemorrhage. Three patients had grade 3 adverse events of hypertension and hand foot syndrome and had temporary termination of treatment. No any patients reduced the dosage of anlotinib therapy because of adverse events. It is worth noting that 7 patients (10.9%) happened grade 1 gastrointestinal bleeding or intratumoral hemorrhage during anlotinib treatment. No treatment-related death happened in this study (Adverse events of anlotinib treatment related.